Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Advanced Cancers
Interventions
DRUG

Pazopanib

Starting dose: 200 mg by mouth every other day starting on day 1 for 28 days.

DRUG

Lapatinib

Starting dose 500 mg by mouth every day for 28 days.

DRUG

Trastuzumab (Herceptin®)

"4 mg/kg loading dose as a 90 minute infusion by vein on day 1 of cycle 1.~Maintenance dose of 2 mg/kg every week as 30 minute infusion by vein.~Dose Expansion Phase: Maximum tolerated dose (MTD) from Dose Escalation Phase"

DRUG

Pazopanib

Starting dose 200 mg by mouth every day for 28 days.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT01454804 - Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors | Biotech Hunter | Biotech Hunter